Following its acquisition of Larix in 2019 and Cmed Group in 2021, Aixial Group has become a leading mid-size, global CRO, with strong US and European presence and more than 1,000 employees. Now, Larix Sweden changes name to Aixial Sweden.
With over 30 years’ experience in successful project delivery, Aixial Group continues to grow with the full integration of Larix and Cmed enabling it to extend its expertise and offerings, with more options for biotech and pharma sponsors at both the local and global levels.
This merger marks a beneficial union that will continue to offer unparalleled industry expertise and a continuum of proven services and technologies to meet the unique demands of today’s complex clinical trials around the world.
Learn more in the press release and visit our brand new web site.